OUTLOOK THERAPEUTICS, INC. Notes Payable, Current
OUTLOOK THERAPEUTICS, INC. (OTLK) had Notes Payable, Current of $3.61 million as of 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Long-Term Debt, Current Maturities › Notes and Loans Payable, Current › Notes Payable, Current
us-gaap:NotesPayableCurrent · last filed 2019-08-14
- 2019-06-30: Notes Payable, Current $3.61M.
- 2019-03-31: Notes Payable, Current $3.61M.
- 2018-12-31: Notes Payable, Current $4.61M.
- 2018-09-30: Notes Payable, Current $4.61M.
| Period end | Notes Payable, Current |
|---|---|
| 2019-06-30 | $3.61M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $3.61M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $4.61M 10-Q · filed 2019-02-14 |
| 2018-09-30 | $4.61M 10-Q · filed 2019-08-14 |
| 2018-06-30 | $4.61M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $4.61M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $4.61M 10-Q · filed 2018-02-14 |
| 2017-09-30 | $4.61M 10-K · filed 2018-12-18 |
| 2017-06-30 | $4.61M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $4.61M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $4.61M 10-Q · filed 2017-02-14 |
| 2016-09-30 | $4.61M 10-K · filed 2017-12-29 |
| 2016-06-30 | $4.61M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $9.65M 10-Q · filed 2016-06-27 |
| 2015-09-30 | $14.21M 10-K · filed 2016-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |